Antitumour potential of a polysaccharide‐rich substance from the fruit juice of Morinda citrifolia (Noni) on sarcoma 180 ascites tumour in mice
Authors:
- 5 December 2003
- journal article
- research article
- Published by Wiley in Phytotherapy Research
- Vol. 17 (10) , 1158-1164
Abstract
An immunomodulatory polysaccharide‐rich substance (Noni‐ppt) from the fruit juice of Morinda citrifolia has been found to possess both prophylactic and therapeutic potentials against the immunomodulator sensitive Sarcoma 180 tumour system. The antitumour activity of Noni‐ppt produced a cure rate of 25%–45% in allogeneic mice and its activity was completely abolished by the concomitant administration of specific inhibitors of macrophages (2‐chloroadenosine), T cells (cyclosporine) or natural killer (NK) cells (anti‐asialo GM1 antibody). Noni‐ppt showed synergistic or additive beneficial effects when combined with a broad spectrum of chemotherapeutic drugs, including cisplatin, adriamycin, mitomycin‐C, bleomycin, etoposide, 5‐fluorouracil, vincristine or camptothecin. It was not beneficial when combined with paclitaxel, cytosine arabinoside, or immunosuppressive anticancer drugs such as cyclophosphamide, methotrexate or 6‐thioguanine. Noni‐ppt also demonstrated beneficial effects when combined with the Th1 cytokine, interferon gamma, but its activity was abolished when combined with Th2 cytokines, interleukin‐4 or interleukin‐10, thereby suggesting that Noni‐ppt induces a Th1 dominant immune status in vivo. The combination of Noni‐ppt with imexon, a synthetic immunomodulator, also demonstrated beneficial effects, but not when combined with the MVE‐2 copolymer, a high molecular weight immunomodulator. It was also not effective when combined with interleukin‐2 or interleukin‐12. Copyright © 2003 John Wiley & Sons, Ltd.Keywords
This publication has 26 references indexed in Scilit:
- Postoperative immuno-gene therapy of murine bladder tumor by in vivo administration of retroviruses expressing mouse interferon-γCancer Gene Therapy, 2001
- Phase II evaluation of interleukin-4 in patients with non-Hodgkinʼs lymphoma: a Southwest Oncology Group TrialAnti-Cancer Drugs, 2000
- Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transferGene Therapy, 2000
- Essential Role of Nitric Oxide and Interferon-γ for Tumor Immunotherapy With Interleukin-10Journal of Immunotherapy, 2000
- Activity and safety of DNA plasmids encoding IL-4 and IFN gammaGene Therapy, 1999
- Interleukin-12: A Proinflammatory Cytokine with Immunoregulatory Functions that Bridge Innate Resistance and Antigen-Specific Adaptive ImmunityAnnual Review of Immunology, 1995
- Antitumor potential of low-dose chemotherapy manifested in combination with immunotherapy of Viva-Natural, a dietary seaweed extract, on Lewis lung carcinomaCancer Letters, 1990
- Antiviral Efficacy of Imexon in the Rauscher Murine Retrovirus Aids ModelImmunopharmacology and Immunotoxicology, 1990
- Anticancer Potential of Viva-Natural, a Dietary Seaweed Extract, on Lewis Lung Carcinoma in Comparison with Chemical Immunomodulators and on Cyclosporine-Accelerated AKR LeukemiaOncology, 1989
- Effect of Pretazettine and Viva-Natural, a Dietary Seaweed Extract, on Spontaneous AKR Leukemia in Comparison with Standard DrugsOncology, 1988